Genomic analyses have revealed mutational footprints associated with DNA maintenance
gone awry, or with mutagen exposures. Because cancer therapeutics often target DNA …

Cell lines are commonly used as cancer models. The tissue of origin provides context for
understanding biological mechanisms and predicting therapy response. We therefore …

Determining the cancer type and molecular subtype has important clinical implications. The
primary site is however unknown for some malignancies discovered in the metastatic stage. …

Analysis of cancer mutagenic signatures provides information about the origin of mutations
and can inform the use of clinical therapies, including immunotherapy. In particular, …

Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication
time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring …

Background TP53 is a master tumor suppressor gene, mutated in approximately half of all
human cancers. Given the many regulatory roles of the corresponding p53 protein, it is …

BACKGROUND Eggshell contains two layers formed by a dense network of fibrous proteins.
These proteins are highly insoluble in a broad variety of solvents, but their composition …

Ovarian high-grade serous carcinoma (HGSC) represents the deadliest gynecological
malignancy, with 10-15% of patients exhibiting primary resistance to first-line chemotherapy. …

Somatic mutations in human cells have a highly heterogeneous genomic distribution, with
increased burden in late-replication time (RT), heterochromatic domains of chromosomes. …

Abstract Analysis of cancer mutagenic signatures provides information about the origin of
mutations and can inform the use of clinical therapies, including immunotherapy. In particular, …